Helsinn Hlthcare Company Profile

What is the competitive landscape for HELSINN HLTHCARE

HELSINN HLTHCARE has five approved drugs.

There are twenty-six US patents protecting HELSINN HLTHCARE drugs.

There are two hundred and ninety-two patent family members on HELSINN HLTHCARE drugs in fifty-six countries and twenty-five supplementary protection certificates in fifteen countries.

Summary for Helsinn Hlthcare

International Patents:	292
US Patents:	26
Tradenames:	3
Ingredients:	4
NDAs:	5

Drugs and US Patents for Helsinn Hlthcare

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Helsinn Hlthcare	AKYNZEO	fosnetupitant chloride hydrochloride; palonosetron hydrochloride	POWDER;INTRAVENOUS	210493-001	Apr 19, 2018		DISCN	Yes	No	12,208,109		Y
Helsinn Hlthcare	AKYNZEO	fosnetupitant chloride hydrochloride; palonosetron hydrochloride	POWDER;INTRAVENOUS	210493-001	Apr 19, 2018		DISCN	Yes	No	10,208,073
Helsinn Hlthcare	ALOXI	palonosetron hydrochloride	INJECTABLE;INTRAVENOUS	021372-001	Jul 25, 2003		DISCN	Yes	No
Helsinn Hlthcare	ALOXI	palonosetron hydrochloride	INJECTABLE;INTRAVENOUS	021372-002	Feb 29, 2008		DISCN	Yes	No
Helsinn Hlthcare	AKYNZEO	fosnetupitant chloride hydrochloride; palonosetron hydrochloride	POWDER;INTRAVENOUS	210493-001	Apr 19, 2018		DISCN	Yes	No	10,717,721			Y
Helsinn Hlthcare	AKYNZEO	fosnetupitant chloride hydrochloride; palonosetron hydrochloride	POWDER;INTRAVENOUS	210493-001	Apr 19, 2018		DISCN	Yes	No	11,529,362		Y

Expired US Patents for Helsinn Hlthcare

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Helsinn Hlthcare	ALOXI	palonosetron hydrochloride	INJECTABLE;INTRAVENOUS	021372-002	Feb 29, 2008	9,439,854*PED
Helsinn Hlthcare	ALOXI	palonosetron hydrochloride	CAPSULE;ORAL	022233-001	Aug 22, 2008	5,202,333
Helsinn Hlthcare	ALOXI	palonosetron hydrochloride	INJECTABLE;INTRAVENOUS	021372-002	Feb 29, 2008	8,518,981*PED
Helsinn Hlthcare	ALOXI	palonosetron hydrochloride	INJECTABLE;INTRAVENOUS	021372-001	Jul 25, 2003	5,202,333*PED
Helsinn Hlthcare	ALOXI	palonosetron hydrochloride	INJECTABLE;INTRAVENOUS	021372-002	Feb 29, 2008	7,947,725*PED
Helsinn Hlthcare	ALOXI	palonosetron hydrochloride	INJECTABLE;INTRAVENOUS	021372-001	Jul 25, 2003	7,947,725*PED

International Patents for Helsinn Hlthcare Drugs

Country	Patent Number	Estimated Expiration
China	103121972
Netherlands	301047
Lithuania	2785706
Slovenia	2785706
Lithuania	2722045
Argentina	114946

Supplementary Protection Certificates for Helsinn Hlthcare Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2785706	806	Finland
2785706	PA2020510	Lithuania		PRODUCT NAME: FOSNETUPITANTAS; REGISTRATION NO/DATE: EU/1/15/1001 20200316
1035115	CA 2015 00044	Denmark		PRODUCT NAME: NETUPITANT; REG. NO/DATE: EU/1/15/1001 20150527
1035115	1590040-0	Sweden		PRODUCT NAME: NETUPITANT; REG. NO/DATE: EU/1/15/1001 20150529
2785706	122020000046	Germany		PRODUCT NAME: FOSNETUPITANT MIT PALONOSETRON; REGISTRATION NO/DATE: C(2020)1804(FINAL) 20200316
0430190	SPC/GB05/032	United Kingdom		PRODUCT NAME: PALONOSETRON OR AN ISOMER, MIXTURE OF ISOMERS, N-OXIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/306/001 20050322

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Helsinn
• Helsinn Hlthcare

Pharmaceutical Competitive Landscape Analysis: Helsinn Healthcare – Market Position, Strengths & Strategic Insights

In the ever-evolving pharmaceutical industry, understanding the competitive landscape is crucial for companies to maintain their edge and drive innovation. Helsinn Healthcare, a Swiss biopharmaceutical group, has carved out a unique position in this dynamic market. Let's delve into Helsinn's market position, strengths, and strategic insights to gain a comprehensive understanding of its role in the pharmaceutical competitive landscape.

Helsinn Healthcare: A Brief Overview

Helsinn Healthcare is a fully integrated global biopharma company headquartered in Lugano, Switzerland. Founded in 1976 by Dr. Gabriele Braglia, Helsinn has grown from a pharmaceutical licensing business into a fourth-generation family-owned company with a strong focus on improving the lives of cancer patients worldwide[5].

Market Position and Global Reach

Helsinn has established a significant presence in the global pharmaceutical market, particularly in the areas of cancer supportive care, oncology therapeutics, and rare diseases[2]. The company's reach extends to 190 countries through a network of over 40 long-standing partners[6]. This extensive global footprint allows Helsinn to effectively serve patients across diverse geographical regions.

Key Markets and Operations

1. United States: Helsinn operates in the U.S. through its subsidiary, Helsinn Therapeutics (U.S.), Inc., which was established following the acquisition of Sapphire Therapeutics in 2009[5].

2. China: The company has a representative office in Beijing, established in 2012, to address healthcare needs in the Asian market[5].

3. Ireland: Helsinn Birex Pharmaceuticals Ltd., a subsidiary in Ireland, supports the company's integrated supply chain and product development efforts[2].

Core Strengths and Competitive Advantages

1. Integrated Business Model

Helsinn's unique business model enables it to in-license or acquire assets at a late stage of development[2]. This approach allows the company to leverage its expertise in late-stage development and commercialization, particularly in oncology and rare diseases.

2. Strong Commercial Engine

The company has built a robust commercial engine based on its supportive care and cancer therapeutics products. This stable revenue stream provides Helsinn with the financial flexibility to invest in research and development of targeted therapeutics[3].

3. Expertise in Oncology and Rare Diseases

Helsinn has positioned itself as a leader in cancer supportive care and has been expanding its focus to include oncology therapeutics and rare diseases[2]. This specialized expertise sets the company apart in a competitive market.

4. Integrated CMC/Manufacturing/Supply Platform

Helsinn's integrated platform, which encompasses chemistry, manufacturing, and controls (CMC), manufacturing, and supply, is complemented by scientific and technological expertise[2]. This integration allows for efficient product development and commercialization.

5. Strategic Partnerships

The company has established partnerships with over 40 long-standing partners worldwide[6]. These collaborations enable Helsinn to extend its reach and leverage complementary strengths in various markets.

Strategic Initiatives and Future Direction

Fully Integrated Targeted Therapy (FITT) Strategy

In 2022, Helsinn launched its Fully Integrated Targeted Therapy (FITT) strategy, marking a significant shift in the company's focus[3]. This strategy aims to transform Helsinn from a leading cancer supportive care company to a fully integrated targeted therapy company.

Key aspects of the FITT strategy include:

1. Developing a differentiated pipeline of highly innovative oncology assets addressing unmet needs.
2. Reinvesting approximately 35% of revenues from existing commercial products into targeted therapeutics R&D over the next five years.
3. Proactively targeting new opportunities for in-licensing or acquisition[3].

Expansion of Product Portfolio

Helsinn is actively seeking to expand its portfolio of late- and commercial-stage oncology and rare disease products through in-licensing or acquisition[6]. This strategic move aims to strengthen the company's position in these key therapeutic areas.

Focus on Innovation and R&D

The company's commitment to innovation is evident in its significant reinvestment of revenues into research and development. This focus on R&D is crucial for maintaining a competitive edge in the rapidly evolving pharmaceutical landscape.

Market Challenges and Competitive Landscape

While Helsinn has established a strong position in its niche, the company faces competition from larger pharmaceutical companies with more extensive resources. In the myelodysplastic syndromes (MDS) market, for example, Helsinn competes with major players such as Otsuka Holdings Co., Ltd., Takeda Pharmaceutical Company Limited, and Johnson & Johnson Private Limited[4].

"Helsinn has partnership agreements with over 40 long-standing partners worldwide in 190 countries, and is a partner of choice for the biotech and pharma sector due to its expertise and late-stage development and commercialization of oncology and rare disease products." - Riccardo Braglia, Executive Chairman of Helsinn[6]

Financial Strength and Investment

To support its growth strategy, Helsinn has secured financing through an agreement with Oberland Capital[6]. This funding will enable the company to pursue its expansion plans and invest in promising oncology and rare disease assets.

Sustainability and Corporate Responsibility

Helsinn has demonstrated a commitment to sustainability and corporate responsibility. The company has achieved carbon neutrality for four consecutive years, reflecting its dedication to environmental stewardship[9].

Leadership and Organizational Structure

Recent leadership changes at Helsinn include:

• Riccardo Braglia appointed as Executive Chairman
• Dr. Melanie Rolli appointed as Chief Executive Officer
• Giorgio Calderari, former Group General Manager, appointed as Chief Executive Officer[3][6]

These changes align with the company's strategic shift and aim to drive the execution of the FITT strategy.

Key Takeaways

1. Helsinn Healthcare has established a strong position in cancer supportive care and is expanding into oncology therapeutics and rare diseases.
2. The company's integrated business model and global reach provide significant competitive advantages.
3. Helsinn's FITT strategy marks a shift towards becoming a fully integrated targeted therapy company.
4. Strategic partnerships and a focus on late-stage development and commercialization are key to Helsinn's success.
5. The company is actively expanding its product portfolio through in-licensing and acquisitions.
6. Helsinn's commitment to sustainability and innovation positions it well for future growth in the competitive pharmaceutical landscape.

FAQs

1. What is Helsinn Healthcare's primary focus? Helsinn focuses on improving the lives of cancer patients worldwide, with a strong position in cancer supportive care and an expanding focus on oncology therapeutics and rare diseases.

2. How does Helsinn's business model differ from other pharmaceutical companies? Helsinn's unique business model enables it to in-license or acquire assets at a late stage of development, leveraging its expertise in late-stage development and commercialization.

3. What is the FITT strategy, and why is it significant for Helsinn? The Fully Integrated Targeted Therapy (FITT) strategy marks Helsinn's transformation from a cancer supportive care company to a fully integrated targeted therapy company, focusing on developing innovative oncology assets.

4. How does Helsinn maintain its global presence? Helsinn maintains its global presence through a network of over 40 long-standing partners in 190 countries, as well as direct operations in key markets like the U.S. and China.

5. What sets Helsinn apart in the competitive pharmaceutical landscape? Helsinn's integrated CMC/manufacturing/supply platform, expertise in oncology and rare diseases, and strong focus on late-stage development and commercialization set it apart in the competitive landscape.

Sources cited: [1] https://investor.bridgebio.com/news-releases/news-release-details/helsinn-group-bridgebio-pharma [2] https://www.oberlandcapital.com/news-post/helsinn-closes-financing-agreement-with-oberland-capital/ [3] https://www.helsinn.com/news/helsinn-launches-fully-integrated-targeted-therapy-fitt-strategy-and-announces-leadership-and-structural-changes/ [4] https://www.databridgemarketresearch.com/reports/global-myelodysplastic-syndromes-market [5] https://www.helsinn.com/about-us/our-story/ [6] https://www.globenewswire.com/news-release/2023/01/10/2586068/0/en/Helsinn-closes-financing-agreement-with-Oberland-Capital.html [9] https://www.helsinn.com/media/sxbhjsgq/qualityoflife2024.pdf

Last updated: 2025-02-13